Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Revenue projections:

Revenue projections for ZTS
Revenue projections for ZTS

With ZTS's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 3.08400
forwardPE 11.12326
debtToEquity 293.99600
earningsGrowth 0.01200
revenueGrowth -0.00200
grossMargins 0.71738
operatingMargins 0.40721
trailingEps 6.13000
forwardEps 6.64913

ZTS's current ratio is 3.084, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting ZTS has no trouble covering its short-term financial obligations.
ZTS's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
Zoetis Inc.'s elevated debt-to-equity ratio suggests the company is leveraging debt heavily, increasing its financial risk. While this can support growth, it could also lead to challenges if the company's profitability or cash flow weakens.
With both earnings and revenue growth in low territory, ZTS is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
ZTS's positive gross and operating margins indicate that the company is performing profitably. These margins reflect efficient cost control and revenue generation, signaling a strong financial foundation for continued success.
ZTS's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for ZTS's financial performance.

Price projections:

Price projections for ZTS
Price projections for ZTS

Over time, analysts have gradually revised ZTS's price projections downward. This suggests growing concerns about the company's ability to meet previous expectations, pointing to a more conservative outlook.

Insider Transactions:

Insider Transactions for ZTS
Insider Transactions for ZTS


Recent trading of ZTS stock saw 1 sales, with market price at 125.55999755859375 per share.2 purchases of Zoetis Inc. were executed, with market price of 75.50499725341797.An increase in buying activity relative to selling at ZTS's current price might suggest a favorable sentiment among investors. This trend could be interpreted as a sign that the stock has a positive outlook in the near term.

Recommendation changes over time:

Recommendations trend for ZTS
Recommendations trend for ZTS


Zoetis Inc. has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view Zoetis Inc. as a stable option to park their money and potentially benefit from the company's continued growth and profitability.